BEBETTER MED
Bebetter Med operates as a pharmaceutical research and development enterprise with a focus on small molecule oncology drugs.
BEBETTER MED
Social Links:
Industry:
Health Care Medical Oncology Pharmaceutical
Founded:
2012-01-01
Address:
Guangzhou, Guangdong, China
Country:
China
Website Url:
http://www.bebettermed.cn
Total Employee:
51+
Status:
Active
Contact:
020-36657255
Email Addresses:
[email protected]
Total Funding:
499 M CNY
Technology used in webpage:
Euro Pound Sterling Japanese Yen Chinese Server Location
Similar Organizations
Arum Therapeutics
Arum Therapeutics is a pharmaceutical company that discovers and develops novel therapeutics for cancer and oncology diseases.
IntraGel
IntraGel is a pharma company that develops smart injectable gel for sustained release to help oncology patients fight back cancer.
Takeda
Takeda is a biopharmaceutical company that researches and develops pharmaceutical drugs.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Investors List
Yingke Capital
Yingke Capital investment in Private Equity Round - Bebetter Med
Gaoxin Capital
Gaoxin Capital investment in Private Equity Round - Bebetter Med
Lucky Source Funds
Lucky Source Funds investment in Venture Round - Bebetter Med
GreatWall Fund
GreatWall Fund investment in Venture Round - Bebetter Med
Official Site Inspections
http://www.bebettermed.cn
- Host name: 211.149.244.115
- IP address: 211.149.244.115
- Location: China
- Latitude: 34.7725
- Longitude: 113.7266
- Timezone: Asia/Shanghai
More informations about "Bebetter Med"
广州必贝特医药股份有限公司
广州必贝特医药股份有限公司研发中试车间装修工程 环境影响报告书报批前公示. 根据《环境影响评价公众参与办法》（生态环境部令第4号）等的要求，建设单位向生态环境主管部门报批环 …See details»
Bebetter Med - Crunchbase Company Profile & Funding
Bebetter Med raised CN¥499,000,000 / Private Equity from Gaoxin Capital and Yingke Capital. ... Contact Email [email protected]; Phone Number 020-36657255; Bebetter Med operates …See details»
关于我们_广州必贝特医药股份有限公司 - bebettermed.cn
上海医药大学药物化学硕士. 美国弗吉尼亚大学化学系访问学者. 原中南大学兼职教授. 原美上市公司 Curis, Inc. 副总裁. 获美国授权专利 60 余项、中国专利20余项、 发表国际发明专利 40 余 …See details»
About Us_Guangzhou BeBetter Medicine Technology Co, LTD.
M.S. in Medicinal Chemistry from Shanghai Medical University (now Fudan University), Visiting Scholar (Postdoctoral research) at the Department of Chemistry, University of Virginia, former …See details»
Guangzhou BeBetter Medicine Technology Co, LTD.
BeBetter Med’s Pan-mutant EGFR Inhibitor BEBT-109 Phase III Clinical Trial Application is Approved by CDE. Recently, the pan-mutant EGFR inhibitor BEBT-109, developed by …See details»
BeBetter Med Overview | SignalHire Company Profile
Organization Website: bebettermed.cn : Phone Number: 020-36657260: BeBetter Med industries BiotechSee details»
BeBetter Med Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BeBetter Med Inc. of Guangzhou, Guangdong. Get the latest business insights from Dun & Bradstreet.See details»
BeBetter Med | 领英 - 领英 (中国)
BeBetter Med | 在领英上有 62 位关注者。Clinical-stage drug discovery and development of advanced novel medicines for cancer and other severe illnesses. | BeBetter Medicine …See details»
Innovation Science - BeBetter Med
The company is a drug research and development organization that promotes interdisciplinary collaboration across a wide range of expertises. The core technical members possess over …See details»
BeBetter Medicine - Products, Competitors, Financials, Employees ...
BeBetter Medicine is a China-based drug discovery and R&D company. Use the CB Insights Platform to explore BeBetter Medicine's full profile.See details»
BeBetter Med, Inc. (广州必贝特医药技术有限公司) - 药物管线_专 …
了解BeBetter Med, Inc. (广州必贝特医药技术有限公司)公司的药物管线，治疗领域，技术平台，以及它的28项临床试验, 86篇新闻和1篇文献，疾病领域:肿瘤，内分泌与代谢疾病，免疫系统疾 …See details»
BeBetter Med, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.bebettermed.cn. Holding Company | 2012 | Guangdong Sheng, China | 50-100 | www.bebettermed.cn. Last update 19 Sep 2024. Overview. Pipeline. Deal. Translational …See details»
Bebetter Med Company Profile 2024: Valuation, Funding
Bebetter Med General Information Description. Developer of innovative small molecule oncology drugs. The company is committed to research and development of innovative drugs for the …See details»
必贝特医药首款siRNA创新药BEBT-507临床试验申请获CDE受理
2024年9月13日，广州必贝特医药股份有限公司自主研发的用于真性红细胞增多症的小核酸（sirna）创新药“bebt-507注射液”的临床试验申请（ind）已获得国家药品监督管理局药品审评 …See details»
BeBetter Med Inc. successfully holds the sponsors meeting & the …
The sponsors meeting & the first general meeting of shareholders was successfully held at the company headquarters on December 20, 2021. With the approval of all sponsors, the …See details»
Press Releases_Guangzhou BeBetter Medicine Technology Co, LTD.
BEBT-503 is a pan-PPAR agonist developed by BebetterMed, boasting exclusive global intellectual property rights. The trial was a randomized, double-blind. BeBetter Med’s Pan …See details»
必贝特医药治疗乳腺癌一类新药BEBT-209获临床批件
广州必贝特医药技术有限公司自主研发的治疗乳腺癌一类新药bebt-209胶囊已获国家药品监督管理局核准签发的《药物临床试验 ...See details»
BeBetter Med’s First-in-Class New Drug BEBT-908 NDA Accepted
On October 8, 2023, the New Drug Application (NDA) ofBEBT-908, a class I newdrug independently developed byBeBetter Med Inc.has been officially accepted by the China …See details»
First-in-Class药物BEBT-908研究成果在CANCER RESEARCH上发布
必贝特First-In-Class药物BEBT-908相关研究成果“A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy“发表。See details»
BeBetter Med’s BEBT-908 granted Breakthrough Therapy …
On October 13,2021, the Center for Drug Evaluation (CDE) of has granted BeBetter Med’s BEBT-908 "Breakthrough Therapy " designation, which is used for the treatment of patients after at …See details»